Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)

J. Bendell, J. Hubbard, B. H. O'Neil, D. Jonker, A. Starodub, J. Peyton, H. Pitot, T. Halfdanarson, B. Nadeau, J. Zubkus, B. Adesunloye, J. Edenfield, Y. Z. Li, W. Li, Axel F Grothey, L. Borodyansky, C. J. Li

Research output: Contribution to journalArticle

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)iii150-iii151
JournalAnnals of Oncology
Volume28
DOIs
StatePublished - Jun 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Bendell, J., Hubbard, J., O'Neil, B. H., Jonker, D., Starodub, A., Peyton, J., Pitot, H., Halfdanarson, T., Nadeau, B., Zubkus, J., Adesunloye, B., Edenfield, J., Li, Y. Z., Li, W., Grothey, A. F., Borodyansky, L., & Li, C. J. (2017). Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology, 28, iii150-iii151. https://doi.org/10.1093/annonc/mdx302.002